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During replicative cycle of retroviruses, the reverse-transcribed viral DNA is integrated into the cell DNA by the viral integrase (IN)
enzyme. The central core domain of IN contains the catalytic site of the enzyme and is involved in binding viral ends and cell DNA as well as
dimerization. We previously performed single amino acid substitutions in the core domain of an Avian Leukemia and Sarcoma Virus (ALSV)
IN [Arch. Virol. 147 (2002) 1761]. Here, we modeled the resulting IN mutants and analyzed the ability of these mutants to mediate concerted
DNA integration in an in vitro assay, and to form dimers by protein–protein cross-linking and size exclusion chromatography. The N197C
mutation resulted in the inability of the mutant to perform concerted integration that was concomitant with a loss of IN dimerization.
Surprisingly, mutations Q102G and A106V at the dimer interface resulted in mutants with higher efficiencies than the wild-type IN in
performing two-ended concerted integration of viral DNA ends. The G139D and A195V mutants had a trend to perform one-ended DNA
integration of viral ends instead of two-ended integration. More drastically, the I88L and L135G mutants preferentially mediated
nonconcerted DNA integration although the proteins form dimers. Therefore, these mutations may alter the formation of IN complexes of
higher molecular size than a dimer that would be required for concerted integration. This study points to the important role of core domain
residues in the concerted integration of viral DNA ends as well as in the oligomerization of the enzyme.
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Introduction of each viral end are cleaved creating the characteristic CA-During the life cycle of retroviruses, the reverse-tran-
scribed viral DNA is integrated into the host cell DNA by
viral integrase protein (IN). The integration step is essential
for the replicative cycle of retroviruses. The integration
process can be subdivided into three steps: (i) the 3V-
processing during which the two 3V terminal nucleotides0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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E-mail address: ronfort@univ-lyon1.fr (C. Ronfort).OH 3Vends; (ii) the strand transfer or the joining of 3Vviral
ends to host DNA, and finally (iii) the gap filling which
allows the reparation of single-stranded DNA gaps and the
ligation of 5Vviral ends to host DNA. The first two steps
require only two viral elements which are the specific
sequences at viral ends designated as att sequences and
the viral integrase protein (Brown, 1997). By contrast, the
gap-filling step may involve cellular enzymes (Daniel et al.,
1999, 2003; Ha et al., 2001; Yoder and Bushman, 2000).
The integration process is designated as ‘‘concerted inte-
gration’’ because it allows the coordinated integration of
both viral ends at the same site of host DNA. As the result
of this process, the integrated provirus is invariably flanked
by the canonical 5VTG. . .CA 3Vviral ends and the duplica-
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virus specific (Brown, 1997).
The retroviral integrase protein contains three domains,
all necessary for its activity (Engelman et al., 1993; van
Gent et al., 1993). Among them, the central core domain is
the most highly conserved (Bujacz et al., 1995; Khan et al.,
1991; Moreau et al., 2002). It contains a highly conserved
motif composed of two aspartic acids and one glutamic acid,
with a second aspartic acid separated from glutamic acid
invariably by 35 residues. This D, D (35) E motif constitutes
the active site of the protein. Mutation of one of these
residues drastically inhibits catalytic activities of 3V-process-
ing, strand transfer, and disintegration (reverse reaction of
strand transfer) of INs tested in vitro (Engelman and
Craigie, 1992; van Gent et al., 1992), as well as infectivity
of viruses in vivo (Engelman, 1999). In addition to catalytic
activities, the core domain is involved in recognition of viral
ends. Indeed, using chimeric IN proteins, it has been shown
that the core domain together with the C-terminal domain is
responsible for att sequence-specific recognition during 3V-
processing and strand transfer experiments in vitro (Berger
et al., 2001). Furthermore, photo cross-linking experiments
have demonstrated that the two terminal nucleotides and the
invariable CA dinucleotide of the viral ends interact with
residues of the core domain of Human Immunodeficiency
Virus (HIV) IN protein (Esposito and Craigie, 1998; Gerton
et al., 1998) and that two lysine residues within the core
domain are critical for interaction of integrase with viral
DNA (Jenkins et al., 1997). Finally, the core domain is also
involved in binding host DNA because it influences the
choice of integration site as observed in in vitro assays with
chimeric enzymes (Appa et al., 2001; Katzman and Sudol,
1995). The crystallographic structure of the core domain has
been determined for both Avian Leukemia and Sarcoma
Viruses (ALSV) and HIV proteins. Both IN core domains
are dimeric and are composed of 5 h strands and either six
(HIV IN) or five (ALSV IN) a helices (Bujacz et al., 1995,
1996; Chen et al., 2000; Dyda et al., 1994; Goldgur et al.,
1998; Lubkowski et al., 1998a, 1999; Wang et al., 2001;
Yang et al., 2000).
We previously introduced 11 single amino acid substitu-
tions in the ALSV Rous Associated Virus type 1 (RAV-1) IN
core domain and analyzed the 3Vprocessing, strand transfer,
and disintegration catalytic activities of the resulting mutants
(Moreau et al., 2002). In the present study, we examined the
effect of these mutations on the concerted integration process
of two viral ends using an in vitro integration assay. We also
examined the oligomeric state of the resulting proteins.
Furthermore, we used the two-domain structure of Rous
Sarcoma Virus (RSV) IN (Yang et al., 2000) to model the
structure of core mutants analyzed here. Our analyses
focused on residues that were at or close to either the dimer
interface or the catalytic site, as well as on residues con-
served among integrases. These analyzes allow us to identify
specific residues within the core domain important for
concerted integration and multimerization of IN.Results
Reconstitution of the concerted DNA integration assay in
vitro
The in vitro retroviral concerted integration assay has
been previously described by others for ALSV (Aiyar et
al., 1996; Chiu and Grandgenett, 2000, 2003; Hindmarsh
et al., 1999, 2001; Vora and Grandgenett, 1995, 2001;
Vora et al., 1994, 1997) and other retroviruses such as
HIV and Simian Immunodeficiency Virus (SIV) (Brin and
Leis, 2002a, 2002b; Carteau et al., 1999; Gao et al.,
2003; Goodarzi et al., 1995, 1999; Sinha et al., 2002) and
Murine Leukemia Virus (MLV) (Yang and Roth, 2001). It
is composed of a linear donor DNA, a plasmid acceptor
DNA, and recombinant IN. High Mobility Group I
protein (HMGI) [now referred as HMGa1] is added to
the reaction because it has been found to enhance the
concerted integration reaction (Hindmarsh et al., 1999). In
the present report, we used a donor DNA of 326 bp
containing 15 bp of the terminal U3 att sequence at one
end and 12 bp of the U5 att sequence at the other end
(Fig. 1A).
Products of the integration reaction can arise from
concerted or nonconcerted integration processes (Fig.
1B) (Aiyar et al., 1996; Brin and Leis, 2002a, 2002b;
Carteau et al., 1999; Goodarzi et al., 1995; Hindmarsh et
al., 1999, 2001; Vora and Grandgenett, 1995, 2001; Vora
et al., 1994, 1997). Concerted integration products include
those that result from two-ended integration of both viral
ends from a single donor (product a) or from two one-
ended integration of two viral ends from two donors at
the same integration site (generating the linear product b).
Nonconcerted integration products result from one-ended
donor integration of a single donor (product c), from two-
ended integration of a single donor with insertion at
different sites on the acceptor DNA (product d), or from
one-ended donor integration of two or more donors at
different sites on the acceptor DNA (product e). Auto-
integration products, which are the result of the integra-
tion of donor DNA in a second donor DNA, are also
obtained (product f). By using labeled donor DNA, the
integration products were separated on agarose gel and
visualized by autoradiography, and three characteristic
bands were revealed (see Fig. 3A, lane 6). As previously
described by others (Carteau et al., 1999; Vora and
Grandgenett, 2001; Vora et al., 1994), the slowest band
corresponds to a mix of circular forms (RFII products: a,
c and d), the middle band corresponds to the linear b
form (RFIII products), and the fastest band corresponds to
autointegration products (form f). Product e, which
migrates more slowly because two or more donors are
inserted into the target, is observed on some gels, but not
all. A recombinant which migrated slightly faster than
RFII recombinants (identified with an asterisk in Fig. 3A)
has been observed by others (Brin and Leis, 2002a,
Fig. 1. Principle of the concerted integration assay. (A) Representation of the donor DNA. It contains 15 bp of the U3 viral end and 12 bp of the viral U5 end. The
highly conserved CA dinucleotides are in bold. The closed rectangle represents the supF tRNA transcription unit. (B) Schematic representation of the reconstituted
integration reaction with the donor DNA, acceptor plasmid, purified integrase, and HMGI proteins. Concerted integration products include those that result from
use of both ends from a single donor (product a) and from use of different ends from two donors (product b). Note that when two donors are inserted at the same
site, a linear product is synthesized. Nonconcerted integration products result from one-ended integration of a single donor (product c), or two-ended integration of
a single donor with insertion at different sites on the acceptor DNA (product d), or one-ended integration of two donors at different sites on the acceptor DNA
(product e). Autointegrants result from integration of a donor DNA in a second donor DNA (product f ). Adapted from Hindmarsh et al. (2001).
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Goodarzi et al., 1995; Sinha et al., 2002; Vora et al.,
1997); its structure is unknown (Goodarzi et al., 1995).
As a control, the reaction was performed without IN: no
integration products were observed (data not shown),
leading to the conclusion that these bands corresponded
to integration products and resulted from IN enzymatic
activity. Integration products were cleaved with either
BamHI (which cleaves in the donor DNA) or XhoI
enzymes (which cleaves in the acceptor DNA). Structures
of digestion products were fully consistent with assign-
ment of the DNA forms (data not shown).
We also cloned the integration products into MC1061/P3
Escherichia coli bacteria. These bacteria contain drug-resis-
tance markers with amber mutations. Only DNA products
carrying the amber mutation suppressor gene (supF) should
be able to replicate and form colonies under drug selection.
Among the different integration products, one-ended or
multiple one-ended donor integration products (c and e)
and linear products (b) should be lost upon cloning into E.coli. Only circular two-ended forms of integration products
(forms a and d) should be able to replicate (Brin and Leis,
2002a, 2002b). Thus, the cloning analyze enables estimation
of the efficiency of IN proteins to mediate the two-ended
integration process (concerted (form a) or not (form d)).
Between 98 and 324 resistant colonies were obtained
according to the experiment with the wild-type IN. Follow-
ing cloning, isolated integration products were analyzed by
sequencing. Donor DNA–acceptor plasmid junctions were
sequenced to check the accuracy of the integration reaction
(cleavage of viral ends and duplication of short acceptor
DNA sequence). In the present study, 19 clones obtained
with the wild-type protein were sequenced (Table 1). Ten
clones exhibited a duplication of 6 bp and eight clones a
duplication of different size (from 4 to 7 bp). In vivo, the 6-
bp duplication is a hallmark of ALSV viruses (Ju et al.,
1980) although some variations have been observed (Mor-
eau et al., 2000). In vitro, duplications of other size than 6
bp have previously been observed (Aiyar et al., 1996;
Hindmarsh et al., 1999). One clone exhibited a deletion of
Table 1
Sequence analyses of donor–acceptor junction sites produced by wild-type
IN protein
Protein Characteristics Number of
recombinants
Wt Duplications of 6 bp 10
Other duplications (4–7 bp) 8
Deletion in acceptor DNA (150 bp) 1
Total 19
Incorrect cleavage of att sequencea 3
a Among all clone studies, few of them were deleted of more than 2 bp at
one or the other att viral end.
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of two nucleotides at both viral ends and integrated between
the canonical TG and CA dinucleotides, it was interpreted as
the result of an integration process but with incorrect
cleavage of the acceptor DNA. Such integration products
with acceptor DNA deletion could arise from either two
independent one-ended donor integration events (form e) or
from nonconcerted integration of the two ends of one donor
DNA (form d). Assuming that only circular integration
products (a and d, Fig. 1) are amplified in bacteria, we
speculate that this clone was most probably the result of a
nonconcerted integration of the two viral ends at two
different sites on acceptor plasmid DNA (form d, Fig. 1).
Such structures have been previously described by others
(Brin and Leis, 2002a, 2002b; Hindmarsh et al., 1999,
2001). Finally, regarding viral DNA ends, we observed
deletion of more than two expected nucleotides at one or
the other att sequence in three clones.
Description of IN mutants
We previously constructed mutants, each containing
single amino acid substitutions in the core of the RAV-1
IN (Moreau et al., 2002) (Fig. 2). Meanwhile, a 2.5-A˚
structure of the closely related RSV (Rous Sarcoma Virus)
IN has been published (Yang et al., 2000) containing both
the core and the C-terminal domains. In this structure, the
two core domains are related by a 2-fold symmetry axes,
whereas C-terminal domains have a similar fold but
associate asymmetrically. The core domain of ALSV INs
consists of five stranded mixed h sheet flanked by five a
helices (Fig. 2) (Bujacz et al., 1995; Yang et al., 2000).
Interface of the dimer is created between the a1 helix in
one monomer and the a5 helix in the complementary
molecule. Further, residues from the h3 strand, which is
located deeper within the monomer, contribute to the
middle part of the dimer interface (Bujacz et al., 1995;
Yang et al., 2000).
The 11 single mutants studied here can be separated
into three structural groups: (1) Q102G, A106V, G186P,
A195V, and N197C were mutated on residues at the
dimeric molecular interface or close to it; (2) D121E,
G123P, and F126I were mutated on residues at or close tothe catalytic site; (3) and three other mutants I88L,
L135G, and G139D were studied as well (Fig. 2 and
Table 2).
(1) Q102 is in helix a1, which is in contact with helix a5 of
the symmetry related monomer at the dimeric interface
(Fig. 2B). The side chain of Q102makes strong hydrogen
bonds with residues S130 and T131 of the same
monomer (Table 2). The Q102 residue has an intermo-
lecular contact with E187 of the other monomer. The
mutation Q102G cancels this network of interactions.
A106 is also located at the surface of helix a1 at the
dimeric interface. Its side chain makes Van der Waals
contacts with residue E187 and A190 of the symmetry
related monomer (Table 2). The A106V mutation creates
a new contact in the dimer (with K191) (Table 2). A
valine can well be accommodated at this site (for
instance, a leucine is found in equivalent position in
HIV IN).
G186 and A195 are part of helix a5, which is in contact
with helix a1 of the symmetry related monomer. Unlike
Q102 and A106, these two residues do not face helix a1
(Fig. 2). The two mutations G186P and A195V create
new contacts inside the monomer (with Q185 and H103
in mutant G186P and R166 in mutant A195V). Note that
proline is known as helix breaker. In consequence, helix
a5 may start at residue 187 in the mutant G186P, and not
at residue 182 as in the wild type.
N197 is located at the end of helix a5, but it is not
involved in intermolecular contacts in the dimer (Table
2). This asparagine is strictly conserved in integrases and,
hence, is supposed to participate in important IN
function. This residue displays an alternate conformation
in the high-resolutions structures of ASVIN_AS and of
ASVIN_HEP (Lubkowski et al., 1999). The mutation
N197C reduces the number of contacts inside the
monomer.
(2) D121 is one of the three fundamental acidic residues of
the catalytic site, D64 and E157 being the others
(Bujacz et al., 1995). In structures, a magnesium ion is
present in the catalytic site and interacts with the
carboxylate groups of the fundamental aspartates D64
and D121. Four water molecules complete the octahe-
dral coordination (Bujacz et al., 1996). The mutation
D121E removes a contact within the monomer (with
F126) and prevents the correct coordination of the
divalent cation.
G123 is strictly conserved in all retroviruses bearing the
catalytic triad DDE. Main chain angles (B, c) of G123
are characteristic of an allowed h-strand conformation.
Thus, the mutant G123P may retain the overall fold of
ALSV IN. However, the main chain nitrogen atom N of
G123 establishes a strong hydrogen bond with the
carboxylic group of the fundamental residue D121 (note
that such contacts with the carbon skeleton are not
mentioned in the table). This liaison can be determinant
Fig. 2. IN core domain mutants. (A) Alignment of amino acid sequences of the ASV and HIV-1 integrases catalytic domains, with the elements of secondary
structure indicated (adapted from Bujacz et al., 1995; Yang et al., 2000). Arrows indicate the amino acids mutated in the present study. (B) Ribbon
representation of the dimeric core domain of ALSV integrase (residue 54–207) (adapted from (Yang et al., 2000)). To increase clarity of the figure, C-terminal
domains (residues 208–268) have been omitted. Labels on the right subunit correspond to the 11 mutated residues discussed in this paper. Labels on the left
subunit indicate a-helix and h-strands.
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consequence, essential for the catalytic mechanism. In
mutant G123P, this contact is replaced by a contact with
the side chain of D121. This could modify the
orientation of D121. The mutation also creates two
new contacts with C125 and F126.
F126 is a highly conserved residue of helix a2. It is part
of the catalytic region and positioned at 8 A˚ away from
the catalytic residue D121. F126 is accessible to solvent
and, thus, could allow an important hydrophobic
stacking of the protein with the DNA at the active site.
The mutation F126I reduces contacts within the
monomer, reinforces a contact (with H142), and maycancel the above-mentioned hydrophobic stacking of the
protein with the DNA.
(3) I88 is a well-conserved residue in strand h3. The residue
is involved in several intramolecular contacts. The
mutation I88L induces changes in these contacts (M193
instead of V81 and L163).
L135 is comprised in helix a3, which is not involved in
intermolecular interactions, and is positioned away from
the active site. The mutation L135G removes all
contacts of L135 within the monomer.
G139 is a well-conserved residue that makes the
transition between helix a3 and strand h5. Its main
chain angles (B, c) are characteristic of a left handed a-
Table 2
Contacts between residues in monomers and dimers of the wt and mutant
INs
ASV Location Contacts between








Q102G Helix a1 S98, S130, T131,
W134, E187b
/
A106V Helix a1 E187b, A190b E187b, A190b, K191b




/ D121, C125, F126
F126I Helix a2 V101, W105, T120,
D121, C125, H142
T120, C125, H142







G186P Helix a5 / Q185, H103
A195V Helix a5 / R166
N197C Helix a5 A87, I88, R201,
P208
I88
a Maximum contact distance is 4 A˚, residues in italic show contact distances
<3.2 A˚.
b Indicates residues of the second subunit in the dimer.
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probably a critical residue for the correct folding of
ALSV IN. This residue is not in contact with another
residue neither in the wild-type protein nor in the mutant
G139D (Table 2).
In a preliminary study (Moreau et al., 2002), mutants
were tested for their 3V-processing and strand transfer
activities using oligonucleotides that mimic the final 15 bp
of att sequence (see Table 4). The activities of mutants were
compared to that of the wild-type protein. I88L, A106V,
L135G, G139D, G186P, and A195V mutants displayed
levels of activity similar or close to that of the wild-type
protein. G123P and N197C displayed reduced levels of
activities (30–60% that of wild-type protein). The D121E
mutant displayed a reduced level of 3V-processing activity
(30–60% that of wild type) and a strongly reduced strand
transfer activity (0–30%). Finally, mutations Q102G and
F126I displayed reduced efficiency to perform the 3V-pro-
cessing activity (30–60%) whereas strand transfer activity
was close to that of the wild-type protein (Moreau et al.,
2002) (Table 4).
Analyses of IN mutants in the concerted integration assay
Mutants were analyzed with respect to their ability to
perform an integration process using the reconstituted in
vitro assay (Fig. 3A). For each mutant, integration efficien-
cy was determined on gel by the intensity of bandscorresponding to RFII and RFIII products (forms a + b +
c + d) and in comparison to the wild-type protein (Fig. 3B,
black bars). The experiments were repeated at least two
times.
Gel analyses demonstrated that four mutations (D121E,
G123P, F126I, and N197C) reduced significantly the inte-
gration process of the resulting mutants (Figs. 3A and 3B,
lanes 4, 5, 7, and 12; and Table 4, column 6). By contrast,
the Q102G mutant (lane 2) showed an integration efficiency
similar to that of the wild-type protein (lane 6). Finally,
some mutants displayed an integration efficiency slightly
lower as compared to the wild-type protein (L135G and
G186P, Fig. 3A, lanes 8 and 10) or slightly higher (I88L,
A106V, G139D, and A195V; lanes 1, 3, 9, and 11) (Fig. 3B
and Table 4).
Afterwards, we focussed on the ability of IN mutants to
perform two-ended integration.
Firstly, integration products were cloned into MC1061/
P3 E. coli bacteria to amplify the two-ended integration
products. For each mutant, the two-ended integration effi-
ciency was determined by the number of clones obtained
relatively to the number of clones obtained with the wild-
type protein. The experiment was performed at least two
times. G139D, G186P, and A195V mutants had an efficien-
cy slightly reduced when compared with that of the wild-
type IN (between 70% and 90%) for two-ended donor
integration. Two other mutants (I88L and F126I) were less
efficient than wild-type IN (approximately 40% of the
efficiency of the wild-type IN) (Fig. 3B). Mutations of four
residues (D121, G123, L135, and N197) drastically
inhibited the two-ended integration process. Unexpectedly,
two mutants, Q102G and A106V, appeared to be more
efficient than the wild-type IN in catalyzing the two-ended
integration process.
For some mutants, the gel analyze (Fig. 3B, black bars)
was in good agreement with the cloning analyze (grey bars).
Indeed, (i) mutants D121E, G123P, F126I, G186P, and
N197C were less efficient than the wild-type protein in
performing integration as revealed on gel and after intro-
duction of reactions into the bacteria. This suggests that
these mutants are less efficient than wild-type IN in
performing all kinds of integration (1- and 2-ended) (noted
‘‘1 and 2’’ in Table 4, column 7), (ii) the A106V mutant was
more efficient than the wild-type protein in performing
integration as revealed in both tests, which suggests that
this mutant is more efficient than the wild-type IN in
performing all kinds of integration (1- and 2-ended) (1
and 2, Table 4). By contrast, for mutant Q102G, the number
of colonies recovered from bacteria was greater than the
number of colonies recovered with the wild-type IN, while
efficiency of integration revealed on gels was similar to that
of the wild-type IN. This strongly suggests that mutant
Q102G is specifically more efficient than the wild-type IN
in performing two-ended DNA integration (noted 2 > 1 in
Table 4). For mutants I88L, G139D, and A195V, the
concerted integration reaction was enhanced as revealed
Fig. 3. Analyses of integration products obtained with the wild-type IN protein and mutants. (A) Using radiolabelled donor DNA, integration products obtained
with wild-type IN protein and mutants were analyzed on 1.2% agarose gel. The letters above indicate the mutation: the first letter is the original residue, the
number its position in the protein, and the second letter the residue that it was substituted into. Next to the picture are schematized integration products.
(Bottom) Percentage of b product (RFIII forms relative to total integration products RFIII/(RFII + RFIII)). * structure of this recombinant is unknown. (B)
Quantification of integration products (forms a + b + c + d) shown in A (in black) and total number of colonies recovered after the reaction products were
introduced into bacteria (in grey). Integration efficiency of wild-type protein was set as 100%. 100% is defined as 98–324 colonies per plates (according to
experiments), derived from reactions with wild-type IN. Results are from at least two experiments.
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wild-type IN on bacteria (40%, 80%, and 90% of the
efficiency of the wild-type IN, respectively). This suggeststhat these three mutants are more efficient than wild-type IN
in performing the one-ended integration process, but are less
efficient in performing the two-ended integration process.
Table 3
Sequence analyses of donor–acceptor junction sites produced by IN mutant
proteins
Protein Characteristics Number of
recombinants
I88L Duplications of 6 bp 9
Other duplications (4–7 bp) 4
Deletion in acceptor DNA 0
Total 13
Incorrect cleavage of att sequencea 3
Q102G Duplications of 6 bp 6
Other duplications (4–7 bp) 7
Deletion in acceptor DNA (316–504 bp) 2
Total 15
Incorrect cleavage of att sequencea 0
A106V Duplications of 6 bp 6
Other duplications (5–9 bp) 9
Deletion in acceptor DNA (14 bp) 1
Total 16
Incorrect cleavage of att sequencea 5
G139D Duplications of 6 bp 9
Other duplications (5–9 bp) 6
Deletion in acceptor DNA (292 bp) 1
Total 16
Incorrect cleavage of att sequencea 7
a Among all clone studies, few of them were deleted of more than 2 bp at
one or the other att viral end.
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DNA integration instead of two-ended DNA integration
(this is noted 1 > 2 in Table 4). More drastically, mutant
L135G was slightly less efficient than wild-type IN in
performing the reaction as observed on gel (70%), but it
was much less efficient for two-ended integration as
revealed on bacteria. These results suggest that among the
integration products generated by this mutant and observed
on gels, there was a lesser proportion of circular two-ended
integration products amplified on bacteria as compared with
the wild-type protein. Thus, the L135G mutant appears to be
specifically altered in performing the two-ended integration
process (noted 1 > 2 in Table 4).
Secondly, the RFIII products containing the linear b form
were quantified separately (Fig. 3A, bottom) as this form
was supposed to result from one event of two-ended
concerted DNA integration (Fig. 1B). For each mutant,
results are given as the percentage of product b relative to
the total integration products (RFIII/RFII + RFIII) (Fig. 3A,
bottom). Product b represents 26% of the total integration
products generated by wild-type IN. It represents from 25%
to 29% for mutants I88L, L135G, G139D, and A195V.
Therefore, there are no relevant differences between these
mutants and the wild-type IN regarding the ratio of product
b among total integration products. Only mutants G186P in
one hand, and mutants Q102G and A106V in the other
hand, displayed reduced and increased proportion of prod-
uct b (17% and 34–37%, respectively).
Overall, results of quantification of the two-ended inte-
gration events (cloning efficiency on bacteria and product b)
are not in accordance. Only two mutants (Q102G and
A106V) displayed concomitantly an enhanced ability in
performing two-ended DNA integration, as revealed by
both experiments. Mutant G186P displayed a concomitant
reduced activity in both tests. For others, a decrease in two-
ended integration on gels was not accompanied by a
decrease of product b (see Discussion).
Molecular characterization of integration products
After cloning, integration products obtained with some of
the mutants were analyzed. We sequenced products of two
mutants with reduced efficiency in performing the two-
ended integration (I88L and G139D) as well as products
of two mutants with enhanced efficiency (Q102G and
A106V) (Table 3).
Between 13 and 16 clones, depending of the mutant,
were sequenced. Overall, the integration products were
similar to those obtained with the wild-type protein. Most
of them presented a short duplication of acceptor DNA
whose sizes ranged from 4 to 9 bp. As for wild-type protein,
a deletion of acceptor DNA (ranging from 14 to 504 bp) was
observed in a few clones (in one clone for A106V and
G139D mutants and in two clones for Q102G mutant).
Several clones showed incorrect cleavage of the att se-
quence: three clones for I88L, five clones for A106Vmutant, and seven clones for G139D mutants. In conclusion,
these analyses show that mutants I88L, Q102G, A106V, and
G139D performed a correct integration process, roughly
comparable to that of the wild-type IN, with correct cleav-
age of viral ends and small-size duplication of acceptor
DNA. We can note a higher number of clones displaying
incorrect cleavage with the G139D mutant than with other
mutants.
Oligomeric state of IN
It has been reported that IN acts as a multimeric complex
during integration. It was proposed to act as a dimer
(Vincent et al., 1993), a tetramer (van Gent et al., 1993;
Wang et al., 2001), or even as an octamer (Bao et al., 2003;
Cherepanov et al., 2003; Heuer and Brown, 1998) during
the integration process. ALSV and HIV INs are present as
mono-, di-, and tetramers in solution, as shown by size
exclusion chromatography, analytical ultracentrifugation,
and cross-linking (Andrake and Skalka, 1995; Bao et al.,
2003; Cherepanov et al., 2003; Coleman et al., 1999;
Deprez et al., 2000; Jenkins et al., 1996; Jones et al.,
1992; Vercammen et al., 2002). Mutants which are less
efficient than the wild-type protein for two-ended concerted
integration (I88L, D121E, G123P, F126I, L135G and
N197C) were therefore tested for their ability to form a
complex by protein–protein cross-linking and size exclu-
sion chromatography.
In the protein–protein cross-linking experiment, the
proteins were incubated with the cross-linker disuccini-
mydyl suberate (DSS) and reaction products were analyzed
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in the absence of IN, we did not observed any product (Fig.
4A, lane 1); in the absence of cross-linker, we observed only
the monomeric form of IN (Fig. 4A, lane 2). With wild-type
IN and in the presence of DSS, we detected products at the
expected molecular weight of integrase monomers and
dimers (Fig. 4A, lane 3). With the exception of N197C
mutant (lane 9), all mutants gave a profile similar to the
wild-type protein profile and were revealed as monomeric
and dimeric complexes. Furthermore, the intensity of theFig. 4. Analyze of oligomeric state of wild-type integrase and mutants. (A)
Protein–protein cross-linking experiments. Proteins were incubated in the
presence of disuccinimidyl suberate (DSS). Reaction products were analyzed
on 10% polyacrylamide gel and revealed by western blot with an anti-Tag
Histidine antibody. The migration of cross-linked species, consistent with the
molecular size of monomers and dimers, are marked. IN: without
integrase, DSS: without disuccinimidyl suberate. (B) Size exclusion
chromatography of wild-type IN protein and N197Cmutant. Elution profiles
of wild-type (WT) IN and N197C mutant are shown. The molecular size of
monomer protein is 36.7 kDa. For reference, the elution positions of three
globular molecular mass standards are indicated with dotted vertical lines.
Retention times, given in minutes, are indicated on x-axis.cross-linked product was roughly the same as the one
observed with wild-type protein. On the contrary, the
N197C protein was not cross-linked by DSS and only the
monomeric form was observed on gel. All other mutants
described in the present study (Q102G, A106V, G139D,
G186P, and A195V) have also been tested by cross-linking,
and all of them presented a profile similar to that of the
wild-type protein (data not shown).
The size exclusion chromatography analyses confirmed
the results of cross-linking analyses. Under the conditions
used, the wild-type protein eluted at a position consistent
with a molecular size of dimers (Fig. 4B). The N197C
mutant presented a different profile and eluted at a position
consistent with the molecular size of monomers (Fig. 4B).
All other mutants tested by size exclusion chromatography
(D121E, G123P, F126I, L135G) eluted at a position con-
sistent with a dimeric complex (data not shown).
Results of both experiments demonstrated that the
N197C mutation rendered the IN enzyme unable to form
dimers. All other mutants studied here were able to form
dimeric complexes.Discussion
In this study, we analyzed both the functional activities
of several points mutants in the core domain of an ALSV
IN in a concerted DNA integration assay in vitro and the
oligomeric state of these mutants. Our analysis focused on
residues at or close either to the active site of the enzyme
or to the core domain dimer interface as well as on highly
conserved residues. Similar analyses have been performed
on residues in the C-terminal domain (Moreau et al.,
in press).
A compilation of data obtained for each mutant in the
core domain studied here and previously (Moreau et al.,
2002) is reported in Table 4. In general, results of concerted
integration on gel were in good agreement with catalytic
activities of 3V-processing and strand transfer. Thus, mutants
which act efficiently in the concerted integration test such as
I88L, A106V, G139D, and A195V (which are slightly more
efficient than the wild-type IN) as well as mutants L135G
and G186P (which are slightly less efficient than the wild-
type IN) had high activities of 3V-processing and strand
transfer. For four other mutants (D121E, G123P, F126I, and
N197C), a reduced activity of concerted integration on gel is
correlated with a decrease either of the 3V-processing activity
or of the strand transfer activity or of both activities.
Surprisingly, mutant Q102G, which displayed a reduced
activity of 3V-processing (55% that of the wild-type IN), was
nevertheless able to perform concerted DNA integration
with the same efficiency of the wild-type IN.
In the in vitro concerted DNA integration assay, we could
evaluate the ability of IN to catalyze two-ended concerted
DNA integration by two ways: (i) by quantifying the linear
product b, because this product is supposed to be generated
Table 4
Compilation of data for each mutant
Mutationa Conservationb Catalytic activitiesc DNA IC test Oligomeric




I88L C ++++ +++ ++++ c 1 > 2 D
Q102G* – ++ +++ ++++ ! 2 > 1 D
A106V* – ++++ ++++ ++++ c 1 and 2 D
D121E C ++ + ++++ jj 1 and 2 D
G123P C ++ ++ ++++ jj 1 and 2 D
F126I C ++ +++ ++++ jj 1 and 2 D
L135G – +++ +++ ++++ j 1 H 2 D
G139D C ++++ ++++ ++++ c 1 >2 D
G186P – ++++ ++++ ++++ j 1 and 2 D
A195V – +++ ++++ ++++ c 1 > 2 D
N197C C ++ ++ ++ jj 1 and 2 M
a The * indicates residues involved in the dimer interface.
b C: residues conserved among INs, as shown by sequences alignments (Moreau et al., 2002) and crystallographic data.
c Data not shown and data from Moreau et al. (2002). 3V-P, 3-processing; S.t., strand transfer; +, 0–30% activity of the wt IN; ++, 30–60%; +++, 60–
90%; ++++ >90%.
d Data from Moreau et al. (2002).
e Results from Fig. 4. D: dimers. M: monomers.
f Results from Fig. 3B. Changes (increase or decrease) in integration efficiencies as revealed on gel, and in comparison with wild-type IN efficiency.
g Results from Fig. 3C. 1 and 2: the 1- and 2-ended DNA integration events increase or decrease concomitantly by comparison with the 1- and 2-ended DNA
integration events of the wild-type IN. 1 > 2:1-ended DNA integration events are favored more than the 2-ended DNA integration events. 2 > 1: 2-ended DNA
integration events are favored more than the 1-ended DNA integration events.
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donors (Aiyar et al., 1996; Brin and Leis, 2002a, 2002b;
Hindmarsh et al., 1999, 2001) (Fig. 1B); (ii) by quantifying
the number of colonies recovered after cloning of integra-
tion products into the bacteria, which allow selective am-
plification of the two-ended circular integration products [a
(concerted) and d (nonconcerted)]. The products a and d
were subsequently distinguished by sequencing of integra-
tion products, and gross deletions of acceptor DNA were
assigned to two-ended nonconcerted DNA integration
events (class d) (Brin and Leis, 2002a, 2002b; Hindmarsh
et al., 2001). In our experiments, most products were of type
a (without deletion of acceptor DNA) (Tables 1 and 3).
Therefore, cloning of integration reactions into bacteria
gives a relevant estimation of product a, and subsequently,
of the two-ended concerted DNA integration events.
According to these assays, if an IN mutant performs two-
ended integration less efficiently than wild-type IN, we
expect a concomitant decrease both in the ratio of product
b among the total integration products and in the number of
recovered colonies from bacteria. Unexpectedly, we found
that the quantity of product b did not systematically match
the recovered number of colonies (Fig. 3B). This is partic-
ularly striking for mutant I88L (lane 1), for which the ratio
of product b was similar to that of wild-type proteins (29%
and 26%, respectively), whereas the ratio of two-ended
integration products amplified in bacteria was reduced to
about 40% of that observed with wild-type IN. Such a
discrepancy is also evident for mutant L135G (lane 8).
Similar observations have previously been made by us when
analyzing mutants of IN in the C-terminal domain (Moreauet al., in press) and by others (Hindmarsh et al., 2001; Vora
et al., 1997). For instance, the ability of a U5 mutated donor
to undergo concerted DNA integration in vitro was 1.5–2-
fold greater than that observed with a wild-type donor
substrate. This stimulation of integration concerned both
the RFII (a + c + d) and RFIII (b) products. However, when
integrants were introduced into bacteria, the number of
colonies recovered was reduced to 25% relative to the
wild-type donor (Hindmarsh et al., 2001). Altogether, these
independent observations show that: (i) when the quantity of
the total integration products revealed on gel increases, the
quantity of product b increases in a similar proportion, (ii)
whereas, in the same reaction, the quantity of product a (and
d) may decrease in an independent manner. Furthermore,
only a significant increase in the two-ended integration
reaction quantified on gel (34–37% of product b), as
observed for Q102G and A106V, was accompanied by an
increase in the recovered number of clones from bacteria.
Therefore, we speculate that product b is a mix of several
linear products resulting from both nonconcerted and con-
certed events of integration and, hence, that quantification of
product b is not strictly relevant to the two-ended integration
products.
The core domain contains the catalytic site of the IN
enzyme (Engelman and Craigie, 1992; van Gent et al., 1992).
Three mutations examined were at residues of the catalytic
site of the core domain (D121E) or close to it (G123P and
F126I). As expected, we observed that the D121E mutation
completely inhibits concerted integration in vitro, as deduced
from gel analyses and cloning experiment (Table 4). Struc-
turally, D121 interacts with magnesium ion. The mutant
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the correct coordination of the divalent cation. Mutation of
the G123 residue, which is very close to the D121 active site
residue and is highly conserved among INs (Bujacz et al.,
1995; Moreau et al., 2002) (Fig. 2A), also completely
inhibited the concerted integration process. On the basis of
structural data, the mutant G123P may retain the overall fold
of ALSV IN. However, mutation G123P, which changes the
liaison between residues G123 and D121, may disturb the
orientation of the D121 residue, and hence, may render the
protein inactive. Mutation of the nearby highly conserved
F126 residue also induced a reduction in integration effi-
ciency. The mutation F126I may cancel an important hydro-
phobic stacking of the protein with the DNA at the active
site. Consequently, the nucleotide segment may not be firmly
bound in the mutant, which could impair the activity of the
mutant.
The core domain is also involved in dimerization of the
protein and the isolated domain has been found to dimerize
(Bujacz et al., 1995, 1996; Lubkowski et al., 1999). Some
mutants studied here [Q102 and A106V (a1) and G186P,
A195V, and N197C (a5)] are part of the secondary struc-
tures involved in the dimer interface (Fig. 2).
Mutation of the N197 residue drastically impaired dimer
formation (Fig. 4). The N197 residue is positioned at the end
of the a5 helix and is close to the dimer interface but is not
involved in contacting with the other monomer (Fig. 2B,
Table 2). It is possible that a cystein residue cannot adopt
the alternate conformation observed for the asparagine
(Lubkowski et al., 1999). This alternate conformation may
be necessary for the correct folding of helix a5 and, thus, for
the formation of the dimeric interface. Alternatively, it is
possible that the monomer of N197C IN is not folded
correctly, which may impair formation of the dimer. Indeed,
the N197 residue makes contact with the A87 residue of the
h3 strand, which the mutation N197C cancels. Concomi-
tantly to dimer impairment, the N197C protein was unable
to perform concerted integration. We had also previously
shown that the N197C mutant interacts with DNA with a
weaker efficiency than does the wild-type protein (Table 4,
Moreau et al., 2002). Thus, defect of the N197C mutant for
concerted integration may be due to its inability to associate
as a dimer or to its weak ability to bind DNA, or both.
By contrast, the mutation Q102G removes contact in the
dimer within the a1 helix (Fig. 2B). Nevertheless, size
exclusion chromatography and cross-linking experiments
conducted with Q102G show that it had the same elution
profile as the wild-type protein and was folded as a dimer. It
is possible that mutating this residue was not sufficient by
itself to impair the formation of the dimer. Conversely,
mutation A106V in the a1 helix reinforces contacts within
the dimer (Table 4). Accordingly, this mutant is folded as a
dimer. To our surprise, both mutants were more efficient
than the wild-type protein in performing two-ended con-
certed integration as deduced from both gel and cloning
analyzes of integration products (Fig. 3). This result sug-gests that among the integration products observed on gel,
there is a high proportion of two-ended concerted integra-
tion products able to be amplified in bacteria. Accordingly,
the ratio of product b was found to be enhanced for both
mutants (Fig. 3B). Furthermore, the processes of integration
were correct as revealed by sequence analysis of integration
products (Table 3). Mutation Q102G, which reduces the
number of contacts within the monomer, is expected to
generate a more flexible protein while the A106V mutation,
which increases the number of contacts within the monomer
and the dimer, is supposed to generate a more rigid protein
(Table 2). As these two mutations have the same effect in
increasing the two ended-integration events, changes in
plasticity of the protein do not explain the increased ability
for concerted integration. It is well known that IN protein
has other functions in addition to integration in the replica-
tive cycle of retroviruses, such as precursor polyprotein
processing, particle assembly and release, DNA synthesis,
and nuclear import (Bouyac-Bertoia et al., 2001; Engelman
et al., 1995; Shin et al., 1994). Therefore, it may be possible
that these two residues in the a1 helix, whose mutations
induce a more active protein for integration, are essential for
other functions of IN in the replicative cycle and are not the
best one for integration. To test this hypothesis, we are
analyzing these mutants in the context of a replicative cycle.
G186 and A195 are part of helix a5, which is in contact
with the above-mentioned helix a1 of the symmetry related
monomer. However, these two residues do not face helix a1,
unlike Q102 and A106 which face a5. Mutations G186P
and A195V affect only slightly the property of the protein
(A195V only increases the one-ended events of integration
over the two-ended integration). Thus, it seems that muta-
tions at the dimer interface between a1 and a5 alter more
significantly the concerted mechanism than mutations at the
sides of the interface.
The highly conserved G139 makes the transition between
helix a3 and strand h5 and appears to be a critical residue
for the correct folding of ALSV IN. The mutant G139D
performed concerted integration with high efficiency. How-
ever, almost half of the clones (7/16) generated by this
mutant were incorrectly cleaved and contained deletions of
att sequences (Table 3). This suggests that the overall
conformation of the mutant G139D may be different from
that of the wild type. This may cause a mispositionning of
the substrate resulting in ectopic cleavages of att extremities
but without reducing efficiency of the integration process.
Finally, mutant L135G and mutant I88L to a lesser extent
presented interesting profiles. Both mutants are active for 3V-
processing and strand transfer and both are also able to bind
DNAwith the same efficiency as wild-type protein (Moreau
et al., 2002) (Table 4). In the concerted integration assay,
they exhibited an integration efficiency close to that of the
wild-type protein, as observed on gel (130% and 75%,
respectively), but there was a significant reduction in the
proportion of integration products recovered when intro-
duced into bacteria (about 40% for I88L and 1% for
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products observed on gel, there was a lower proportion of
two-ended integration products (able to replicate in bacteria)
for I88L and L135G mutants than for wild-type protein.
Therefore, these mutations appear to reduce more specifi-
cally the two-ended integration process. For the I88L
mutant, sequencing of integration products revealed that,
when two-ended integration occurred, it was correct (Table
3). Furthermore, size exclusion chromatography and cross-
linking experiments demonstrated that these mutated pro-
teins were present as a dimer complex, like the wild-type
protein. Altogether, these observations are consistent with a
disruption of a higher-order IN complex necessary for two-
ended integration. Indeed, different authors have suggested
that the minimal IN structure for concerted integration may
be a tetramer (Bao et al., 2003; Cherepanov et al., 2003;
Heuer and Brown, 1998; Vora and Grandgenett, 2001; Yang
et al., 2000). Therefore, we suggest that I88L and L135G
mutations may alter the formation of higher molecular size
complexes than dimers resulting specifically in a reduction
in two-ended concerted DNA integration. It is possible that
these residues are directly involved in the formation of the
tetramer. However, this assumption is not in accordance
with structural data. Indeed, I88L and L135G residues are
part of the interior core of the protein, and therefore are
unlikely to be involved in tetramer formation. Therefore,
these mutations most likely induce conformational changes
that either have local effects that prevent the formation of a
tetramer or have distal effects that affect the global structure
of the protein.
In summary, our results show the importance of residues
of the core domain in IN oligomerization and concerted
integration. Our data show a strong structural role of
residue N197 in ALSV IN dimerization, and the impor-
tance of residues Q102 and A106 at the dimer interface in
the efficiency of two-ended concerted integration. They
also predict a potential role for the L135 residue, and to a
lesser extent the I88 residue, in the architecture of the
molecule. These residues of the protein may constitute new
targets for the development of antiviral drugs against
integrase.Materials and methods
DNA manipulation
The DNA pBSK-Zeo acceptor plasmid was constructed
as follows. The pBSK + plasmid (Stratagene) was digested
by SmaI and SacII restriction enzymes, subjected to the
Klenow enzyme, and reclosed by ligation to generate pBSK
+ DBamHI plasmid. pBSK + DBamHI plasmid was then
digested by HindIII and EcoRV, subjected to the Klenow
enzyme, and reclosed by ligation to generate pBSK + D2
plasmid. These manipulations removed the BamHI and
EcoRV restriction sites. Afterwards, pBSK + D2 plasmidwas amplified by PCR using the Pfu turbo polymerase
enzyme (Stratagene) and BU (5VCCGATATCATACTC-
TTCC3V) and BL (5VCCGATATCAGACCAAGTTTAC3V)
primers. In the same way, the zeo gene was amplified from
the pHook.3 plasmid (Invitrogen) using Z1 (5VCCGATAT-
CGTGTTGACAATTAATC3V) and Z2 (5VCCGATATCC-
AGACATGATAAGATAC3V) primers. All primers contain
an EcoRV restriction site and the resulting PCR products,
pBSK + D2 and the zeo gene, were digested by the EcoRV
restriction enzyme and ligated together giving the pBSK-zeo
plasmid. This plasmid, which is zeocin resistant, was ampli-
fied in DH5a bacteria (Invitrogen).
The donor DNAwas obtained as follows. The supF gene
was amplified by PCR from piVX plasmid (ATCC) using
H-sup1 (5VGAGAAGCTTAACGTTGCCCGGATCCGGTC
3V) and P-sup2 (5VGAGCTGCAGTAGTCCTGTCGGGTT-
TCGCC 3V) primers containing HindIII and PstI restriction
sites, respectively. The amplification product was digested
with HindIII and PstI restriction enzymes and ligated into
the pBSK + plasmid digested by the same restriction
enzymes giving pBSK-supF plasmid. The donor DNA was
then amplified from pBSK-supF plasmid by PCR using the
pfu turbo polymerase enzyme, U3 (GATGTAGTCTTATAC-
GTTGCCCGGATCCGG 3V) and U5 bis (5VAATGAAG-
CCTTCTGCTTTGAGCGTCGATTTTTG 3V) primers. The
PCR product was purified from agarose gel using the Qiaex
II kit (Qiagen). The final donor DNA contained 15 bp of the
U3 end sequence of the Avian Erythroblatosis Virus (AEV)
and 12 bp of the U5 end sequence.
Modeling of the mutants
Construction of IN mutants has been reported elsewhere
(Moreau et al., 2002). Numerous crystallographic struc-
tures of the core domain of ASV IN have been solved
under different crystallization conditions (changes in pH
and in precipitant agents) (Bujacz et al., 1995, 1996;
Lubkowski et al., 1998a, 1998b, 1999). Several residues
in alternate conformation have been observed in the two
highest resolution structures, determined at 1.02 A˚ resolu-
tion in presence of ammonium sulphate (named ASVI-
N_AS) and at 1.06 A˚ resolution in presence of HEPES
(named ASVIN_HEP) (Lubkowski et al., 1999). Two two-
domain structures of Rous Sarcoma Virus (RSV) IN,
containing the core and the C-terminal region, have been
solved in space groups P21 and P1 at 3.1 and 2.5 A˚
resolution, respectively (Yang et al., 2000). No structure
containing also the N-terminal domain has been published
yet. In consequence, the 2.5-A˚ two-domain structure of
RSV IN was used to model the structure of mutants.
Modeling has been performed on the dimer. Each structure
of single mutant has been generated using the program
CALPHA (Esnouf, 1997) and minimized with the program
CNS using a conjugate gradient method (Brunger et al.,
1998). Resulting models were displayed and analyzed on a
graphic station using the program TURBO-FRODO (Rous-
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ed with CNS around each mutated residue. During struc-
tural analysis, the high-resolution structures of ASVIN_AS
and ASVIN_HEP have been superimposed with the mod-
els and displayed on graphic station so as to check if the
structures of ASVIN cores share a similar topology at the
mutated regions. In parallel, a BLAST search (Altschul et
al., 1997) was performed against the SWISS-PROT and the
TrEMBL sequence databases (Bairoch and Apweiler, 2000)
to detect homologous proteins. A multiple sequence align-
ment was performed in turn with CLUSTAL (Thompson et
al., 1994): the 11 studied substitutions are unique in
retrovirus as well as in lentivirus integrases.
Purification of proteins
The RAV-1 IN coding sequences (wild type or mutants)
were cloned into the pET30a plasmid (Invitrogen) beyond a
six histidine tag. IN proteins were expressed in BL21
bacteria (Invitrogen) and purified as described by others
(Puras Lutzke and Plasterk, 1998).
The pET15b-HMGI expressing vector was generously
donated by T.H. Kim, Cambridge, USA (Thanos and
Maniatis, 1992). The High Mobility group type I (HMGI)
proteins were expressed in BL21 (DE3) pLysS bacteria
(Invitrogen) in the presence of 100 Ag/ml of ampicillin
and 34 Ag/ml of chloramphenicol upon induction with 1
mM of IPTG for 3 h. Purification was conducted as follows.
The bacteria pellet was resuspended in PBS plus 0.1% of
triton before sonication. Then 5% of perchloric acid was
added and the solution was incubated for 30 min at 4 jC.
The lysate was then centrifuged for 10 min at 12000  g. A
total of 25% of trichloroacetic acid was added to the
supernatant, which was then incubated for an hour on ice.
After 10 min centrifugation at 12000  g, the pellet was
rinsed once with acetone and 0.2% HC1 (20 jC), twice
with acetone 70%, ethanol 20%, 20 mM Tris–HCl, pH
8 (20 jC), and once with acetone (20 jC). The pellet
was then dried at room temperature before being resus-
pended in 250 Al of Tris–EDTA. The solution was then
passed through a Hitrap Heparin column (Pharmacia),
which was previously equilibrated with 0.5 M NaCl, 50
mM NaH2 PO4, pH 7.4 solution. The column was washed
with 0.5 M NaCl, 50 mM NaH2 PO4, pH 7.4 solution and
the proteins were eluted with a gradient from 0.5 to 1.5 M of
NaCl. Each fraction was analyzed by Bradford quantifica-
tion and Western blot.
Integration reaction
A total of 60 ng of purified IN protein was incubated
overnight at 4 jC with 100 ng of pBSK-zeo plasmid, 10
ng of donor DNA, and 100 ng of purified HMGI protein
in a final volume of 5 Al. The volume of reaction was
then increased to 20 Al with a final concentration of 20
mM HEPES, pH 7.5, 1 mM DTT, 30 mM MgCl2, 15%DMSO, 8% PEG 8000, and 50 mM NaCl, and the
integration mixture was incubated at 37 jC for an hour
and a half.
Gel analyses of the integration reaction
For gel analyses of the integration reaction, the DNA
donor was radiolabelled by including 8 ACi of dCTPa32P in
the PCR amplification mixture. After the integration reac-
tion was performed, the volume was increased to 50 Al with
the addition of 4.25 mM of EDTA, 0.44% of SDS, and 20
ng of proteinase K (Roche diagnostics) and samples were
incubated for 1 h at 55 jC. The DNAs were deproteinized
by phenol-chloroform extraction and purified by ethanol
precipitation. Samples were then loaded on 1.2% agarose
gel in 0.5 TBE. After electrophoresis, the gels were fixed
in a 5% TCA solution for 30 min and dried for 3 h at 45 jC.
Lastly, the gels were exposed to autoradiographic film
overnight at 80 jC. Integration products were quantified
using a phosphoimager (Biorad).
Cloning and sequencing of two-ended integration products
To clone integration products for sequencing, products
of the integration reaction were purified on a Qiaquick
column (Qiagen) as described by the supplier. The whole
reaction was introduced into MC10610/P3 E. coli bacteria
(Invitrogen) as described by others (Aiyar et al., 1996).
MC1061/P3 E. coli bacteria contain ampicillin-, tetracy-
clin-, and kanamycin-resistant genes. Both ampicillin- and
tetracyclin-resistant genes carry an amb mutation. These
proteins are thus expressed only in the presence of the supF
gene products. Among the different integration products,
only circular plasmids carrying the supF gene were able to
replicate and form colonies. Integration clones carrying
both zeocin-resistant and supF genes were therefore select-
ed in the presence of 40 Ag/ml of ampicillin, 10 Ag/ml of
tetracyclin, 15 Ag/ml of kanamycin, and 25 Ag/ml of
zeocin. Under these conditions, we detected no colony
when donor and acceptor DNAs were transfected to cell
in the absence of IN. According to the experiment, we
were able to detect between 100 and 300 colonies with the
wild-type IN protein. Plasmids were isolated from quadru-
ply resistant colonies and donor–acceptor DNA junctions
were sequenced using SL primer (5VACTCTAAATCTGC-
CGTCATCG 3V) for the U3 junction and SU primer (5V
ATCATATCAAATGACGCGCCG 3V) for the U5 junction.
SL and SU primers are located on the donor DNA.
Size exclusion chromatography
All proteins were centrifuged for 10 min at 14000 rpm
to remove IN aggregates. A total of 100 Al of integrase
solution at a concentration of 30 AM was loaded on a
Superoz 12 column (Pharmacia) previously equilibrated
with 1 M NaCl, 25 mM HEPES, pH 7.5, 0.1 mM EDTA,
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chromatography was performed at 4 jC. The column
was calibrated with molecular mass markers. Protein
elution was monitored at A280 nm at a flow rate of
0.3 ml/min.
Protein–protein cross-linking
Wild-type or mutant integrases were treated with 40
Ag/ml disuccinimidyl suberate (Pierce). Reactions included
2 Ag of protein in a final volume of 10 Al of 20 mM
HEPES, pH7.5, 60 mM NaCl, 0.7 mM EDTA, 10%
glycerol, and 4.5 mM CHAPS. Following 30 min at 22
jC, reactions were quenched by the addition of 3 mM of
Lysine and 25 mM of Tris–HCl (pH 8). After 10 min at
22 jC, reactions were boiled for 10 min in sample buffer
and electrophoresed in SDS page (10%). Products were
revealed by Western blot using anti-His-tag antibody
(Roche Diagnostics).Acknowledgments
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